Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Eli Lilly & Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Short-term borrowings and current maturities of long-term debt
Accounts payable
Employee compensation
Sales rebates and discounts
Other current liabilities
Current liabilities
Long-term debt, excluding current maturities
Long-term income taxes payable
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Common stock
Additional paid-in capital
Retained earnings
Employee benefit trust
Accumulated other comprehensive loss
Other equity
Total Eli Lilly and Company shareholders’ equity
Noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


An examination of the balance sheet reveals notable shifts in liabilities and stockholders’ equity over the observed period, spanning from March 2021 to December 2025. Overall, both total liabilities and total equity demonstrate an increasing trend, particularly accelerating in the later years of the period.

Current Liabilities
Current liabilities exhibited volatility throughout the period, peaking at US$27.293 billion in December 2023 before decreasing to US$21.998 billion in September 2023 and then rising again to US$35.228 billion in December 2025. A significant driver of this fluctuation appears to be sales rebates and discounts, which increased substantially from US$5.821 billion in March 2021 to US$17.382 billion in December 2025. Accounts payable also showed a consistent upward trend, increasing from US$1.640 billion to US$5.379 billion over the same period. Employee compensation also increased, but less dramatically, from US$0.650 billion to US$2.375 billion.
Noncurrent Liabilities
Noncurrent liabilities generally remained relatively stable between March 2021 and December 2022, fluctuating around US$26 billion. However, a marked increase is observed from March 2023 onwards, reaching US$50.713 billion by December 2025. This increase is largely attributable to a substantial rise in long-term debt, excluding current maturities, which grew from US$18.881 billion in March 2023 to US$40.868 billion in December 2025. Long-term income taxes payable also increased, but to a lesser extent.
Total Liabilities
Total liabilities mirrored the trends in its components, increasing from US$39.739 billion in March 2021 to US$85.941 billion in December 2025. The most significant increase occurred between September 2024 and December 2025, suggesting a period of increased borrowing or accrual of obligations.
Stockholders’ Equity
Total stockholders’ equity also demonstrated an upward trajectory, rising from US$7.099 billion in March 2021 to US$26.535 billion in December 2025. Retained earnings contributed significantly to this growth, increasing from US$9.181 billion to US$24.470 billion. Additional paid-in capital also increased, though at a slower rate. Accumulated other comprehensive loss decreased over the period, partially offsetting the increases in other equity components. Common stock remained relatively constant.

The observed increases in both liabilities and equity suggest a period of expansion and investment for the company. The substantial growth in sales rebates and discounts may indicate increased promotional activity or changes in revenue recognition policies. The significant rise in long-term debt warrants further investigation to assess the company’s debt servicing capacity and financial risk.